A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Metabolism-Regulating Nanozyme System for Advanced Nanocatalytic Cancer Therapy
Tekijät: Liu Chang, Xu Xiaoyu, Chen Yongyang, Yin Miao, Mäkilä Ermei, Zhou Wenhui, Su Wenmei, Zhang Hongbo
Kustantaja: WILEY-V C H VERLAG GMBH
Kustannuspaikka: WEINHEIM
Julkaisuvuosi: 2024
Journal: Small
Tietokannassa oleva lehden nimi: SMALL
Lehden akronyymi: SMALL
Artikkelin numero: 2307794
Vuosikerta: 20
Numero: 24
Sivujen määrä: 12
ISSN: 1613-6810
eISSN: 1613-6829
DOI: https://doi.org/10.1002/smll.202307794
Verkko-osoite: https://doi.org/10.1002/smll.202307794
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/387055604
Nanocatalytic therapy, an emerging approach in cancer treatment, utilizes nanomaterials to initiate enzyme-mimetic catalytic reactions within tumors, inducing tumor-suppressive effects. However, the targeted and selective catalysis within tumor cells is challenging yet critical for minimizing the adverse effects. The distinctive reliance of tumor cells on glycolysis generates abundant lactate, influencing the tumor's pH, which can be manipulated to selectively activate nanozymatic catalysis. Herein, small interfering ribonucleic acid (siRNA) targeting lactate transporter-mediated efflux is encapsulated within the iron-based metal-organic framework (FeMOF) and specifically delivered to tumor cells through cell membrane coating. This approach traps lactate within the cell, swiftly acidifying the tumor cytoplasm and creating an environment for boosting the catalysis of the FeMOF nanozyme. The nanozyme generates hydroxyl radical (center dot OH) in the reversed acidic environment, using endogenous hydrogen peroxide (H2O2) produced by mitochondria as a substrate. The induced cytoplasmic acidification disrupts calcium homeostasis, leading to mitochondrial calcium overload, resulting in mitochondrial dysfunction and subsequent tumor cell death. Additionally, the tumor microenvironment is also remodeled, inhibiting migration and invasion, thus preventing metastasis. This groundbreaking strategy combines metabolic regulation with nanozyme catalysis in a toxic drug-free approach for tumor treatment, holding promise for future clinical applications.Emerging nanocatalytic therapies utilize nanomaterials to induce tumor inhibition through enzyme-like reactions. Lactate-targeted siRNAs in FeMOF can be selectively delivered to tumor cells, triggering intracellular acidification, enhancing the catalytic effect of the nano-enzymes, generating hydroxyl radicals and calcium influx, and disrupting mitochondrial function to eliminate tumors, while simultaneously remodeling the tumor microenvironment to inhibit tumor migration and metastasis.image
Ladattava julkaisu This is an electronic reprint of the original article. |  |
